Home / Companies / Reviva Pharmaceuticals Holdings, Inc. / 10 Dec 2024
Reviva Pharmaceuticals Holdings, Inc.: meeting of 10 Dec 2024
Votes reported on Form N-PX, item by item
27 Form N-PX filers reported votes at the Reviva Pharmaceuticals Holdings, Inc. meeting of 10 Dec 2024. Their records fall into 6 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
5 nominees; 78.0% of reported votes for; 4 filers withheld from or voted against at least one nominee.
50 vote records from 6 filers. 2 of the 6 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
34 vote records from 27 filers. 3 of the 26 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Frequency of the say-on-pay vote
one year: 24 filers; abstain: 1 filer; against: 1 filer; not applicable: 1 filer.
34 vote records from 27 filers. 2 of the 26 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
10 vote records from 6 filers. 0 of the 6 filers that marked the item either way voted against management.
CAPITAL STRUCTUREIssuer
CAPITAL STRUCTURE: management items
Management items in this category are shown together; filers word and number them differently.
10 vote records from 6 filers. 0 of the 6 filers that marked the item either way voted against management.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
10 vote records from 6 filers. 0 of the 6 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Pay-vote frequency | 4. Auditor |
|---|---|---|---|---|
| Vanguard | For | For | Split or no vote | For |
| BlackRock and iShares | Abstain or withhold * | For | Split or no vote | For |
| Fidelity | For | For | Split or no vote | For |
| State Street and SPDR | No report | For | Split or no vote | No report |
| Equitable | Abstain or withhold * | For | Split or no vote | For |
| John Hancock and Manulife | For | For | Split or no vote | For |
| Northern Trust and FlexShares | No report | For | Split or no vote | No report |
| BNY Mellon | No report | For | Split or no vote | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Reviva Pharmaceuticals Holdings, Inc. meeting?
27 Form N-PX filers reported votes at the meeting of 10 Dec 2024. On say-on-pay, 3 of 26 voted against management (11.5%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Reviva Pharmaceuticals Holdings, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Reviva Pharmaceuticals Holdings, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Reviva Pharmaceuticals Holdings, Inc. with a meeting date within three days of 10 Dec 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.